International Alport Syndrome Meeting Report Published

KFOC, Pedersen Family and Partners award two new 2014 Alport Syndrome Research Grants

Dr. Adeera Levin Awarded Kidney Foundation of Canada’s 2014 Medal for Research Excellence

First Nations Adults with Diabetes Have More than Double the Risk of End-Stage Kidney Disease

Dr. Marcello Tonelli Awarded 2013 Medal for Research Excellence for Changing Nephrology Practice in Canada and Beyond

Paying Living Kidney Donors May Be Cost-Effective and Help Prolong Lives

The Kidney Foundation congratulates Dr. Andreas Laupacis on being awarded the inaugural CIHR Barer-Flood Prize in Health Services and Policy Research

New Research to Discover a Cure for Rare Kidney Disease

CSN Announces Editor in Chief of New Journal

Dr. Adeera Levin appointed President of the International Society of Nephrology

Sugary Drinks May Increase Risk of Kidney Stones

Launch of new Canadian National Transplant Research Program

Alberta Researchers Receive Top Achievement in Health Research Award

Kidney Foundation of Canada Helps Fund World’s First Gene Therapy Clinical Trial for Fabry Disease

First-of-Its-Kind Canadian Project to Chart the Future of Dialysis Research

Lead Investigator on Landmark Walkerton Health Study Awarded 2012 Medal for Research Excellence

New Drug Shows Hope for ADPKD Treatment

New Findings Debunk Long-Held Theory that Kidney Disease is Part of the Normal Aging Process

The Kidney Foundation of Canada partners with Kidney Cancer Canada and Government to support national research network

Thu, 24 Jan 2013

Kidney Foundation of Canada Helps Fund World’s First Gene Therapy Clinical Trial for Fabry Disease

January 24, 2013 - Canadian researchers, led by Dr. Jeffrey Medin, are launching the world’s first gene therapy clinical trial for Fabry disease. A rare genetic disease due to a deficiency, or the absence, of an enzyme that breaks down fatty material in the body, Fabry disease affects many organ systems. Kidney complications in Fabry Disease are common and serious. End-Stage Renal Disease typically occurs in the third decade of life and is a leading cause of death.

Gene therapy introduces corrective factors to address deficiencies caused by abnormal or absent genes. The clinical trial being led by Dr. Medin builds on his gene therapy research in experimental animal models. In gene therapy, a patient’s stem cells are removed from the blood. Then, a working copy of a new gene (with a working enzyme) is inserted into the stem cells and transplanted back into the patient. In this way, the corrective biological catalyst or enzyme  will circulate in the body. 

“Funding innovative research that reduces the burden of kidney disease was one of the founding purpose of The Kidney Foundation of Canada. Today, our support of this cutting edge clinical trial demonstrates our commitment to research that can lead to treatment breakthroughs for people living with kidney disease, regardless of its root cause. We are honored to be among the supporters of this work and will continue to finance kidney-related research whether the disease is manifested as a chronic disease, cancer, acute kidney damage, or a result of genetic factors such as Fabry disease,” says Dr. Julian Midgley, National President of The Kidney Foundation of Canada. “We also recognize that stem cell research is particularly critical to providing hope for better treatment options to kidney patients.”

Download the press release from Alberta Health Services